Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis
Takashi Yokoyama, Mayuka Nakatake, Takeshi Kuwata, Arnaud Couzinet, Ryo Goitsuka, Shuichi Tsutsumi, Hiroyuki Aburatani, Peter J.M. Valk, Ruud Delwel, Takuro Nakamura
Takashi Yokoyama, Mayuka Nakatake, Takeshi Kuwata, Arnaud Couzinet, Ryo Goitsuka, Shuichi Tsutsumi, Hiroyuki Aburatani, Peter J.M. Valk, Ruud Delwel, Takuro Nakamura
View: Text | PDF
Research Article Oncology

MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis

  • Text
  • PDF
Abstract

The TALE-class homeoprotein MEIS1 specifically collaborates with HOXA9 to drive myeloid leukemogenesis. Although MEIS1 alone has only a moderate effect on cell proliferation in vitro, it is essential for the development of HOXA9-induced leukemia in vivo. Here, using murine models of leukemogenesis, we have shown that MEIS1 promotes leukemic cell homing and engraftment in bone marrow and enhances cell-cell interactions and cytokine-mediated cell migration. We analyzed global DNA binding of MEIS1 in leukemic cells as well as gene expression alterations in MEIS1-deficent cells and identified synaptotagmin-like 1 (Sytl1, also known as Slp1) as the MEIS1 target gene that cooperates with Hoxa9 in leukemogenesis. Replacement of SYTL1 in MEIS1-deficent cells restored both cell migration and engraftment. Further analysis revealed that SYTL1 promotes cell migration via activation of the CXCL12/CXCR4 axis, as SYTL1 determines intracellular trafficking of CXCR4. Together, our results reveal that MEIS1, through induction of SYTL1, promotes leukemogenesis and supports leukemic cell homing and engraftment, facilitating interactions between leukemic cells and bone marrow stroma.

Authors

Takashi Yokoyama, Mayuka Nakatake, Takeshi Kuwata, Arnaud Couzinet, Ryo Goitsuka, Shuichi Tsutsumi, Hiroyuki Aburatani, Peter J.M. Valk, Ruud Delwel, Takuro Nakamura

×

Figure 7

SYTL1 promotes membrane trafficking of CXCR4 and activates downstream signaling.

Options: View larger image (or click on image) Download as PowerPoint
SYTL1 promotes membrane trafficking of CXCR4 and activates downstream si...
(A) Representative immunofluorescence of H9M1, HΔM, or HΔM/SYTL1 cells after the indicated incubation periods with CXCL12 (3 experiments). Alexa Fluor 350–conjugated wheat germ agglutinin (WGA) was used to indicate plasma membrane. Scale bar: 20 μm. (B) The expression of CXCR4 on the surfaces of H9M1, HΔM, or HΔM/SYTL1 cells was analyzed by flow cytometry at the indicated times after CXCL12 stimulation. The cells were incubated with the anti-CXCR4 antibody after (same staining condition as A) or before CXCL12 stimulation. The data are representative of 3 independent experiments. (C) ERK and AKT phosphorylation after CXCL12 stimulation in the indicated cell types; blots are representative of 3 independent experiments. (D) Juxtaposition of H9M1 or HΔM/SYTL1 cells and CAR cells in bone marrow. CAR cells are stained with anti-S100. Representative images of 3 independent experiments. Quantification with statistical analysis is shown in Supplemental Figure 9D. Scale bar: 20 μm. (E) Proposed model showing enhanced membrane trafficking of CXCR4 after SYTL1 upregulation. CXCR4 is internalized and ubiquitinated upon binding to CXCL12. However, CXCR4 is rapidly provided from its reservoir on the limiting membrane of multivesicular bodies in the presence of SYTL1 and Rab27b.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts